The U.S. Food and Drug Administration has approved AstraZeneca blockbuster drug Imfinzi to treat some adults with ...
AstraZeneca has picked off another label expansion for its cancer blockbuster Imfinzi (durvalumab) as the FDA has ...
AstraZeneca and Daiichi Sankyo have shared the data they believe can secure approval for datopotamab deruxtecan (Dato-DXd) at ...
British drug maker AstraZeneca Plc (AZN.L, AZN) announced Thursday that the U.S. Food and Drug Administration has approved Imfinzi ...
US FDA grants priority review status to AstraZeneca’s sBLA for Imfinzi to treat patients with muscle-invasive bladder cancer: Cambridge, UK Saturday, December 7, 2024, 09:00 Hrs ...
AstraZeneca AZN announced that the FDA has approved its blockbuster cancer drug Imfinzi (durvalumab) for treating ...
The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody, Imfinzi (durvalumab), to ...
AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following ...
Imfinzi (durvalumab) for adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed ...
Imfinzi has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer, LS-SCLC ...
Durvalumab was associated with a 27% reduction in the risk for death compared with placebo in the phase 3 ADRIATIC trial.
(Alliance News) - AstraZeneca PLC on Thursday said the US Food & Drug Administration has approved its Imfinzi treatment for adults with limited-stage small cell lung cancer.